4565 — Nxera Pharma Co Balance Sheet
0.000.00%
- ¥82bn
- ¥119bn
- ¥30bn
Annual balance sheet for Nxera Pharma Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 60,173 | 66,557 | 49,381 | 36,203 | 20,365 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2,208 | 2,520 | 7,163 | 9,089 | 10,460 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 62,808 | 69,942 | 65,112 | 57,855 | 44,465 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,817 | 3,791 | 7,900 | 7,468 | 7,455 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 96,985 | 99,417 | 157,198 | 151,498 | 134,787 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7,191 | 4,092 | 17,185 | 15,632 | 17,500 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 39,517 | 41,481 | 90,388 | 82,980 | 73,790 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 57,468 | 57,936 | 66,810 | 68,518 | 60,997 |
| Total Liabilities & Shareholders' Equity | 96,985 | 99,417 | 157,198 | 151,498 | 134,787 |
| Total Common Shares Outstanding |